May. 19 at 7:31 PM
$CLNN One of the more interesting comps for
$CLNN is
$TNGX.
Both share a common high-conviction biotech investor in Boxer Capital.
Go pull up the 1-year chart on TNGX. The stock went from a forgotten small-cap biotech trading around cash levels to a violent market re-rating once the Street started pricing in platform validation, strategic financing strength, and pipeline credibility. Biotech repricings happen fast when sentiment flips.
The reason this matters for
$CLNN is that the setup has similarities:
• years of skepticism
• low expectations
• heavily debated science
• institutional accumulation under the surface
• and now a potentially de-risking regulatory path ahead
Not saying CLNN = TNGX. Different disease, different science, different stage. But the broader lesson is the same: the market can ignore a biotech story for years… until suddenly it can’t.
